在接受高效抗逆转录病毒治疗（HAART）但持续治疗失败的患者中，HIV共受体使用情况稳定。
Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART.
作者信息
Lehmann Clara, Däumer Martin, Boussaad Ibrahim, Sing Tobias, Beerenwinkel Niko, Lengauer Thomas, Schmeisser Norbert, Wyen Christoph, Fätkenheuer Gerd, Kaiser Rolf
机构信息
Department of Internal Medicine, University of Cologne, Germany.
出版信息
J Clin Virol. 2006 Dec;37(4):300-4. doi: 10.1016/j.jcv.2006.08.008. Epub 2006 Sep 26.
BACKGROUND
Disease progression in HIV infection has been associated with switch of viral coreceptor usage from CCR5 to CXCR4.
OBJECTIVES
To investigate the relationship between HIV-coreceptor tropism and clinical and virological outcome in 40 heavily pretreated patients over time.
METHODS
Coreceptor phenotype was predicted after sequencing the V3 loop of the HIV glycoprotein 120.
RESULTS
Coreceptor use was stable during observation time in 87% of patients, and CCR5 tropism was predominant. Viral mutations in the pol gene and clinical parameters were not predictive for coreceptor switching.
CONCLUSIONS
Even in patients with repeated HAART failure, CCR5 antagonists might be a valuable treatment option.
背景
HIV感染的疾病进展与病毒共受体使用从CCR5向CXCR4的转变有关。
目的
随着时间推移，调查40例接受过大量治疗的患者中HIV共受体嗜性与临床和病毒学结果之间的关系。
方法
对HIV糖蛋白120的V3环进行测序后预测共受体表型。
结果
87%的患者在观察期内共受体使用稳定，且CCR5嗜性占主导。pol基因中的病毒突变和临床参数不能预测共受体转换。
结论
即使在多次HAART失败的患者中，CCR5拮抗剂可能也是一种有价值的治疗选择。
Zotero 插件